1. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience.
- Author
-
Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD, Rao BN, and Daw NC
- Subjects
- Adolescent, Adult, Bone Neoplasms pathology, Child, Child, Preschool, Cohort Studies, Disease-Free Survival, Female, Hospitals, Pediatric statistics & numerical data, Humans, Kaplan-Meier Estimate, Male, Medical Records, Neoplasm Grading, Osteosarcoma pathology, Recurrence, Retrospective Studies, Sex Distribution, Tennessee epidemiology, Young Adult, Bone Neoplasms mortality, Osteosarcoma mortality
- Abstract
Background: Chemotherapy has improved the outcome of patients with newly diagnosed osteosarcoma, but its role in relapsed disease is unclear., Methods: We reviewed the records of all patients who were treated for relapsed high-grade osteosarcoma at our institution between 1970 and 2004. Postrelapse event-free survival (PREFS) and postrelapse survival (PRS) were estimated, and outcome comparisons were made using an exact log-rank test., Results: The 10-year PREFS and PRS of the 110 patients were 11.8% ± 3.5% and 17.0% ± 4.3%, respectively. Metastasis at initial diagnosis (14%), and relapse in lung only (75%) were not significantly associated with PREFS or PRS. Time from initial diagnosis to first relapse (RL1) ≥18 months (43%), surgery at RL1 (76%), and ability to achieve second complete remission (CR2, 56%) were favorably associated with PREFS and PRS (P ≤ 0.0002). In patients without CR2, chemotherapy at RL1 was favorably associated with PREFS (P = 0.01) but not with PRS. In patients with lung relapse only, unilateral relapse and number of nodules ( ≤ 3) were associated with better PREFS and PRS (P ≤ 0.0005); no patients with bilateral relapse survived 10 years. The median PREFS after treatment with cisplatin, doxorubicin, methotrexate, and ifosfamide was 3.5 months (95% confidence interval, 2.1-5.2), and the median PRS was 8.2 months (95% confidence interval, 5.2-15.1)., Conclusions: Late relapse, surgical resection, and unilateral involvement (in lung relapse only) favorably impact outcome after relapse. Surgery is essential for survival; chemotherapy may slow disease progression in patients without CR2. These data are useful for designing clinical trials that evaluate novel agents., (© 2013 American Cancer Society.)
- Published
- 2013
- Full Text
- View/download PDF